Analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of CG Oncology in a research report issued to clients and investors on Monday, March 31st. HC Wainwright analyst A. Maldonado ...

Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG ...

Anktiva (nogapendekin alfa inbakicep, or N-803) can be used in combination with the BCG vaccine in non-muscle invasive bladder cancer (NMIBC) patients who had not responded to the BCG shot on its ...

ImmunityBio, Inc.'s advances with Anktiva & rBCG show promise amid financial hurdles. Click here to find out why IBRX stock ...

HC Wainwright issued their FY2029 EPS estimates for CG Oncology in a note issued to investors on Monday, March 31st. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings ...

CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

The FDA application is for the use of TAR-200 as a treatment for high-risk, non-muscle-invasive bladder cancer (NMIBC) that does not respond to BCG, a live bacterial vaccine that is the standard ...

BOSTON & MONTREAL, April 01, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, ...

Gene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The ...